Ipilimumab: tested in a combination
412 studies: another drug in the study is under test too. Page 1 of 5. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCCNot yet recruitingNCT07919717Phase 2Report a problem
- First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingNCT07893340Phase 2Report a problem
- Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingNCT07879599Phase 2/3Report a problem
- Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingNCT07879586Phase 2/3Report a problem
- A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction CancerNot yet recruitingNCT07878221Phase 2Report a problem
- Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II StudyNot yet recruitingNCT07756190Phase 2Report a problem
- Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal CancerRecruitingNCT07751055Phase 2Report a problem
- NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) MelanomaRecruitingNCT07740941Phase 2Report a problem
- Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical TrialNot yet recruitingNCT07715565Phase 2Report a problem
- Timing of Immunotherapy in MelanomaRecruitingNCT07696715Not applicableReport a problem
- Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaRecruitingNCT07689175Phase 2Report a problem
- SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic CancerRecruitingNCT07683221Phase 2Report a problem
- Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaNot yet recruitingNCT07645846Phase 2Report a problem
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT07643623Phase 2/3Report a problem
- Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric CancerNot yet recruitingNCT07638631Phase 2Report a problem
- Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With MelanomaNot yet recruitingNCT07615881Phase 1/2Report a problem
- Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic CancerNot yet recruitingNCT07587827Phase 1Report a problem
- MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.RecruitingNCT07574047Phase 2Report a problem
- Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaRecruitingNCT07560488Phase 2Report a problem
- A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerRecruitingNCT07506109Phase 2Report a problem
- ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabRecruitingNCT07504796Phase 2Report a problem
- Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaRecruitingNCT07501117Phase 1Report a problem
- TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskRecruitingNCT07487662Phase 2Report a problem
- A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular CarcinomaRecruitingNCT07482059Phase 1/2Report a problem
- Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in SloveniaRecruitingNCT07422779Not applicableReport a problem
- A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCCRecruitingNCT07422753Phase 2Report a problem
- Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal CancerNot yet recruitingNCT07403877Phase 2Report a problem
- First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerRecruitingNCT07355205Phase 1/2Report a problem
- The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.Not yet recruitingNCT07338981Phase 3Report a problem
- Neo-adjuvant Immunotherapy in Patients With Localized MelanomaRecruitingNCT07230613Phase 2Report a problem
- Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME TrialRecruitingNCT07155317Phase 2Report a problem
- NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyRecruitingNCT07121374Phase 1/2Report a problem
- Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular CancerRecruitingNCT07075120Phase 1Report a problem
- Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)RecruitingNCT06999980Phase 2Report a problem
- Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)RecruitingNCT06926790Phase 2Report a problem
- Towards Cure Via Only Ultra-short ICB in CSCCRecruitingNCT06823479Phase 2Report a problem
- SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III MelanomaRecruitingNCT06794775Phase 3Report a problem
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingNCT06747845Phase 2Report a problem
- Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesRecruitingNCT06712927Phase 2Report a problem
- Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)RecruitingNCT06683755Phase 1/2Report a problem
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaRecruitingNCT06594991Phase 2Report a problem
- Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingNCT06492421Phase 2Report a problem
- Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2Report a problem
- The Sagittarius TrialRecruitingNCT06490536Phase 3Report a problem
- Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via ITRecruitingNCT06483347Phase 2Report a problem
- Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via ITRecruitingNCT06482801Phase 2Report a problem
- DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCRecruitingNCT06364917Phase 2Report a problem
- CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3Report a problem
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaRecruitingNCT06295159Phase 2Report a problem
- Intradermal Ipilimumab and Nivolumab in High Risk Stage II MelanomaRecruitingNCT06240143Phase 1/2Report a problem
- Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesRecruitingNCT06163820Phase 1/2Report a problem
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4Report a problem
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingNCT05896839Phase 1/2Report a problem
- Cryoablation+Ipilimumab+Nivolumab in MelanomaRecruitingNCT05779423Phase 2Report a problem
- Immunotherapy in Patients With Early dMMR Rectal CancerRecruitingNCT05732389Phase 2Report a problem
- Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaRecruitingNCT05647265Phase 2Report a problem
- Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid SyndromeNot yet recruitingNCT05597800Phase 2Report a problem
- Nivolumab-ipilimumab and Chemoradiation for Cervical CancerRecruitingNCT05492123Phase 2Report a problem
- Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingNCT05361720Phase 2Report a problem
- Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRCRecruitingNCT05310643Phase 2Report a problem
- Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsRecruitingNCT05187338Phase 1/2Report a problem
- Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic CancerRecruitingNCT05088889Phase 1Report a problem
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingNCT05048212Phase 2Report a problem
- BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabRecruitingNCT04933903Phase 2Report a problem
- Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular CarcinomaRecruitingNCT04823403Phase 1Report a problem
- Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare SubtypeRecruitingNCT04741438Phase 3Report a problem
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingNCT04511013Phase 2Report a problem
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingNCT04472767Phase 2Report a problem
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2Report a problem
- A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI StudyRecruitingNCT03844256Phase 1/2Report a problem
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingNCT03816345Phase 1Report a problem
- Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IORecruitingNCT03815890Phase 2Report a problem
- Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid TumorsRecruitingNCT03755739Phase 2/3Report a problem
- Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2Report a problem
- Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaRecruitingNCT03521830Phase 2Report a problem
- Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell CarcinomaRecruitingNCT03406247Phase 2Report a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2Report a problem
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerRecruitingNCT03026140Phase 2Report a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2Report a problem
- Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaTerminatedNCT05200143Phase 2Results postedReport a problem
- A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaCompletedNCT05041062Phase 2Results postedReport a problem
- Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLActive, not recruitingNCT04938232Phase 2Results postedReport a problem
- A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaCompletedNCT04513522Phase 4Results postedReport a problem
- Neoadjuvant Immunotherapy in Brain MetastasesTerminatedNCT04434560Phase 2Results postedReport a problem
- Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersActive, not recruitingNCT04416568Phase 2Results postedReport a problem
- Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated GlioblastomaCompletedNCT04396860Phase 2/3Results postedReport a problem
- A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver CancerCompletedNCT04340193Phase 3Results postedReport a problem
- Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior ImmunotherapyCompletedNCT04326257Phase 2Results postedReport a problem
- Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue SarcomaCompletedNCT04118166Phase 2Results postedReport a problem
- Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaActive, not recruitingNCT04091750Phase 2Results postedReport a problem
- A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaTerminatedNCT04088500Phase 2Results postedReport a problem
- Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results postedReport a problem
- A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryCompletedNCT04026412Phase 3Results postedReport a problem
- A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active, not recruitingNCT04008030Phase 3Results postedReport a problem
- Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaActive, not recruitingNCT03929029Phase 1Results postedReport a problem
- Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerActive, not recruitingNCT03914300Phase 2Results postedReport a problem
- Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain MetastasisTerminatedNCT03903640Phase 2Results postedReport a problem
- Radiation and Combination Immunotherapy for MelanomaCompletedNCT03850691Phase 2Results postedReport a problem
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersActive, not recruitingNCT03816332Phase 1Results postedReport a problem